Johnson & Johnson (JNJ) is Burns J W & Co. Inc. NY’s 9th Largest Position
Burns J W & Co. Inc. NY cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,123 shares of the company’s stock after selling 416 shares during the period. Johnson & Johnson accounts for approximately 2.2% of Burns J W & Co. Inc. NY’s holdings, making the stock its 9th largest position. Burns J W & Co. Inc. NY’s holdings in Johnson & Johnson were worth $7,293,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the company. Investec Asset Management LTD raised its stake in shares of Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock valued at $546,454,000 after buying an additional 1,665,644 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Johnson & Johnson by 2.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 73,530,716 shares of the company’s stock valued at $7,956,023,000 after buying an additional 1,546,408 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in Johnson & Johnson by 12.5% in the first quarter. TIAA CREF Investment Management LLC now owns 13,848,797 shares of the company’s stock valued at $1,498,440,000 after buying an additional 1,534,277 shares during the last quarter. Virginia Retirement System acquired a new position in Johnson & Johnson during the first quarter valued at about $119,842,000. Finally, NN Investment Partners Holdings N.V. acquired a new position in Johnson & Johnson during the first quarter valued at about $92,331,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) traded up 0.73% during midday trading on Friday, hitting $118.13. The stock had a trading volume of 7,941,065 shares. The firm has a market cap of $323.19 billion, a P/E ratio of 22.01 and a beta of 0.61. The stock has a 50-day moving average of $119.23 and a 200-day moving average of $116.66. Johnson & Johnson has a 52 week low of $92.58 and a 52 week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Analysts forecast that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.71%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
JNJ has been the subject of several recent analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a research note on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and issued a $125.00 price target (up previously from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target for the company in a research note on Friday, August 5th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. Finally, Jefferies Group increased their price target on Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a research note on Thursday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $120.19.
In related news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.